Is Regeneron Pharmaceuticals Inc (REGN) overvalued? · P/E 14, rev $14.34B
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
This page asks whether Regeneron Pharmaceuticals Inc (REGN) looks expensive on cached numbers — not a short thesis.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next REGN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the REGN stock page for the full model, not this heading.
Not investment advice.